22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure

This publication has 50 references indexed in Scilit:

• Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study
  Nephrology Dialysis Transplantation, 1996
• Renal bone disease 1990: An unmet challenge for the nephrologist
  Kidney International, 1990
• Affinity of 22-oxa-1,25(OH)2D3 for 1,25-dihydroxyvitamin D receptor and its effects on the synthesis of osteocalcin in human osteosarcoma cells
  Biochemical and Biophysical Research Communications, 1990
• Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal Failure
  New England Journal of Medicine, 1989
• 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial
  Kidney International, 1989
• Synthetic analogues of vitamin D₃ with an oxygen atom in the side chain skeleton A trial of the development of vitamin D compounds which exhibit potent differentiation‐inducing activity without inducing hypercalcemia
  FEBS Letters, 1987
• Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing Dialysis
  New England Journal of Medicine, 1986
• Synthetic studies of vitamin D3 analogues. VIII Synthesis of 22-oxavitamin D3 analogues.
  CHEMICAL & PHARMACEUTICAL BULLETIN, 1986
• Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
  Journal of Clinical Investigation, 1984
• A program package for quantitative analysis of histologic structure and remodeling dynamics of bone
  Computer Programs in Biomedicine, 1981